Results 21 to 30 of about 9,174 (165)
Paraoxonase 1 status in the Thai population [PDF]
Journal of Human Genetics, 2005 Human serum paraoxonase 1 (PON1), a high-density lipoprotein (HDL)-associated enzyme, has been shown to reduce the oxidation of low-density lipoprotein (LDL) and HDL by degrading lipid peroxides. This property of PON1 accounts for its ability to protect against atherosclerosis.
Wimon, Phuntuwate +4 more
openaire +2 more sources
Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates [PDF]
Molecules, 2020 Mammalian paraoxonase-1 hydrolyses a very broad spectrum of esters such as certain drugs and xenobiotics. The aim of this study was to determine whether carbamates influence the activity of recombinant PON1 (rePON1). Carbamates were selected having a variety of applications: bambuterol and physostigmine are drugs, carbofuran is used as a pesticide ...
Anita Bosak +5 more
openaire +5 more sources
The Role of PON1 Variants in Disease Susceptibility in a Turkish Population
Global Medical Genetics, 2020 Paraoxonase 1 (PON1) enzyme plays a major role in antioxidant defense and protects the cells against reactive species. The most common PON1 Q192R and L55M polymorphisms are responsible for a wide variation of PON1 activity, which showed an up to 13-fold ...
Mahmoud Abudayyak +4 more
doaj +1 more source
Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis
Molecules, 2021 Oxidative stress is involved in the pathophysiology of nonalcoholic fatty liver disease (NAFLD). However, reliable biomarkers of NAFLD in relation to oxidative stress are not available.
Kazuhiko Kotani +3 more
doaj +1 more source
Study of Paraoxonase 1 (PON1) Activity as an Independent Risk Factor in Coronary Artery Disease [PDF]
National Journal of Laboratory Medicine, 2013 Background: Coronary Artery Disease is the major cause of mortality and morbidity worldwide. Human serum paraoxonase-1 is a high density lipoprotein bound enzyme exhibiting antiatherogenic properties.
Sangita M. Patil +7 more
doaj +1 more source
Study the levels of Leptin, and Adiponectin with Paraoxonase in Obese Individuals (male & female)
Tikrit Journal of Pure Science, 2023 Obesity is a well-known risk factor of metabolic complications and cardiovascular disease. Associations between anthropometric measurements and fat distribution and risk factors for cardiovascular disease have been demonstrated in several populations.
Entedhar R. Sarhat
doaj +1 more source
The Effects of Bioavailability-Enhanced Curcuminoids on Serum Paraoxonase-1 Activity in Patients with Metabolic Syndrome [PDF]
Journal of Cardio-Thoracic Medicine, 2021 Introduction: Metabolic syndrome (MetS) is characterised by a clustering of metabolic cardiovascular disease (CVD) risk factors that include: central obesity, impaired glucose metabolism, dyslipidaemia (hypertriglyceridemia, increased low-density ...
Atena Raee +7 more
doaj +1 more source
Paraoxonase 1 in Chronic Kidney Failure [PDF]
Journal of Lipids, 2012 In this review we summarize the findings from the literature and our own laboratory on the decreased PON1 activity in renal failure, the mechanisms proposed and the effect of interventions. In addition to profound alterations in lipoproteins, reduced serum PON1 activity has been clearly established in the past decade and could contribute to accelerated
Alejandro Gugliucci +2 more
openaire +2 more sources
Haplotype-Phenotype Relationships of Paraoxonase-1 [PDF]
Cancer Epidemiology, Biomarkers & Prevention, 2005 Abstract Paraoxonase 1 (PON1) is an enzyme with multiple activities, including detoxification of organophosphates. It is believed to be important in preventing neurotoxic damage and has also been implicated in atherosclerosis. The PON1 gene contains five common polymorphisms, three in the promoter (−909G > C, −162A > G ...
Jia, Chen +4 more
openaire +2 more sources
Paraoxonase 1 as an important antiatherogenic agent
Journal of Education, Health and Sport, 2019 The inverse relationship between High Density Lipoproteins (HDL) level and risk of ischaemic heart disease was proved by many epidemiological studies. Although the main mechanism of antiatherogenic activity of HDL is a reverse transport of cholesterol ...
Ewa Lidia Krzewicka-Romaniuk +3 more
doaj +3 more sources